Acalabrutinib is Another BTK Inhibitor    Active drug for Waldenstrom Macroglobulinemia

Acalabrutinib is Another BTK Inhibitor Active drug for Waldenstrom Macroglobulinemia

Annual-Meeting

1 year
130 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Acalabrutinib is Another BTK Inhibitor Active drug for Waldenstrom Macroglobulinemia at Annual Meeting 2018
Up Next Autoplay